Generalized pustular psoriasis in Brazil: A public claims database study.

Autor:	Duarte GV; Instituto Bahiano de Imunoterapia - IBIS, Salvador, Brazil., Esteves de Carvalho AV; Hospital Moinhos de Ventos Porto Alegre, Porto Alegre, Brazil.; Unisinos - Universidade do Vale do Rio dos Sinos, Porto Alegre, Brazil., Romiti R; Dermatology Division, University of São Paulo, São Paulo, Brazil., Gaspar A; Heads in Health - São Paulo, Brazil., Gomes de Melo T; Boehringer Ingelheim do Brasil - Avenida das Nações Unidas, São Paulo, Brazil., Soares CP; Boehringer Ingelheim do Brasil - Avenida das Nações Unidas, São Paulo, Brazil., Aguirre AR; Boehringer Ingelheim do Brasil - Avenida das Nações Unidas, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	JAAD international [JAAD Int] 2022 Jan 12; Vol. 6, pp. 61-67. Date of Electronic Publication: 2022 Jan 12 (Print Publication: 2022).
DOI:	10.1016/j.jdin.2021.12.001
Abstrakt:	Background: Generalized pustular psoriasis (GPP) is a rare and severe phenotype of psoriasis characterized by sudden outbreak of widespread coalescent sterile pustules associated with a spectrum of systemic symptoms. Objective: We aimed to describe the epidemiology and treatment of GPP in Brazil from the public health care system perspective. Methods: This was a retrospective public claims database study, using outpatient and inpatient databases, with information from January 2018 to August 2020, based on records of health resource utilization by patients with GPP. Outpatient treatment regimens and fatal inpatient outcomes were described. Results: In total, 1458 outpatients of all ages were identified, of whom 53% were women. We estimated the GPP prevalence in Brazil to be between 0.7 and 0.9 per 100,000. Acitretin was the most commonly dispensed drug. Of all the outpatients, 769 outpatients could be tracked in the inpatient database, and 151 had hospital admissions during the study period. Of them, 5.3% had a fatal outcome during hospitalization. A primary skin condition or an infection was the most frequent hospitalization cause. Limitation: The International Classification of Diseases codes for GPP and psoriasis have not been previously validated in this context. Conclusion: GPP is a rare disease in Brazil and affects individuals of all ages and both sexes. Hospitalizations and disease-related deaths highlight the need for its prompt diagnosis, close medical follow-up, and effective treatment. Competing Interests: Dr Duarte received grants, consultancy and speaking honoraria from 10.13039/100006483AbbVie, 10.13039/100004326Bayer, Biolab, Boehringer Ingelheim, 10.13039/501100009754Galderma, Janssen, Eli-Lilly, Leo, 10.13039/100011110UCB, 10.13039/100004336Novartis, and 10.13039/100004319Pfizer. Dr Carvalho received grants, consultancy, and speaking honoraria from 10.13039/100006483AbbVie, Janssen, Leo, Boehringer Ingelheim, 10.13039/100004336Novartis, Eli-Lilly, and 10.13039/100011110UCB. Dr Romiti served as a scientific consultant, speaker, or clinical study investigator for AbbVie, Boehringer Ingelheim, Galderma, Janssen-Cilag, Eli-Lilly, Leo-Pharma, Novartis, Pfizer, TEVA, and UCB. Author Gaspar is an employee of Heads in Health. Drs Melo, Soares, and Aguirre are employees of Boehringer Ingelheim do Brasil. (© 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu